Maternal serum placental growth factor combined with second trimester aneuploidy screening to predict small-for-gestation neonates without preeclampsia

Kim, Su Mi; Yun, Hang Goo; Kim, Ra Yon; Chung, Yoo Hyun; Cheon, Ju Young; Wie, Jeong Ha; Kwon, Ji Young; Ko, Hyun Sun; Kim, Yeon Hee; Han, Eun Hee; Park, Joon Hong; Kim, Hyun Jung; Kim, Myungshin; Shin, Jong Chul; Park, In Yang

doi:10.1016/j.tjog.2017.10.017

Cited by 4 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have reported that the increase of inhibin A is associated with the occurrence of preeclampsia, and fetal malformation and fetal growth restriction [2,[6][7][8][9][10], but there are few reports on inhibin A and other maternal and fetal adverse pregnancy outcomes. The purpose of our study was to evaluate the relationship between inhibition of A and preeclampsia, gestational hypertension, gestational diabetes, macrosomia, low birth weight and preterm delivery in Chinese pregnant women.…”

Section: Introductionmentioning

confidence: 99%

Are serum levels of inhibin A in second trimester predictors of adverse pregnancy outcome?

Yue

Zhang

et al. 2020

PLoS ONE

View full text Add to dashboard Cite

ObjectiveDuring pregnancy, inhibin A is mainly derived from the placenta and regulates the implantation and differentiation of embryos. Our aim was to assess whether second trimester serum inhibin A was associated with an increased risk of adverse pregnancy outcomes. MethodsWe investigated the serum levels of Inhibin A during the second trimester in pregnancy, and analyzed associations between the Inhibin A and the risk of adverse pregnancy outcome. 12,124 pregnant women were enrolled in this study between January 2017 and July 2019 at the Obstetrics & Gynecology Hospital of Fudan University. Multivariate logistic regression analysis was conducted to estimate the relative risk between Inhibin A and adverse pregnancy outcome. ResultsCompared with the group without adverse pregnancy outcome, during the second trimester of pregnancy, age and Inhibin A were risk factors for pre-eclampsia, gestational diabetes mellitus and preterm delivery; Inhibin A was risk factors for low birth weight. Gravidity and Inhibin A were risk factors for macrosomia; while parity was a protective factor against preeclampsia, gestational hypertension and low birth weight. ConclusionElevated Inhibin A levels in pregnancy are significantly associated with pre-eclampsia, GDM, macrosomia, low birth weight and preterm delivery.

show abstract

Section: Introductionmentioning

confidence: 99%

Are serum levels of inhibin A in second trimester predictors of adverse pregnancy outcome?

Yue

Zhang

et al. 2020

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…A study by Miranda et al [ 52 ] showed that although mean inhibin A concentrations were significantly higher in women with SGA infants, a multivariable integrative model of maternal characteristics, fetoplacental ultrasound, and maternal biochemical markers only modestly improved the detection of SGA/FGR cases at 32–36 weeks’ gestation when compared with screening based on EFW centiles alone. Other studies [ 53 ] have also shown that the clinical utility of activin A, inhibin A, and follistatin as predictors for SGA/FGR is poor.…”

Section: Hormonal Factors Polypeptides and Glycoproteinsmentioning

confidence: 99%

Circulating biomarkers associated with placental dysfunction and their utility for predicting fetal growth restriction

Hong

Kumar

2023

Clinical Science

View full text Add to dashboard Cite

Fetal growth restriction (FGR) leading to low birth weight (LBW) is a major cause of neonatal morbidity and mortality worldwide. Normal placental development involves a series of highly regulated processes involving a multitude of hormones, transcription factors, and cell lineages. Failure to achieve this leads to placental dysfunction and related placental diseases such as pre-clampsia and FGR. Early recognition of at-risk pregnancies is important because careful maternal and fetal surveillance can potentially prevent adverse maternal and perinatal outcomes by judicious pregnancy surveillance and careful timing of birth. Given the association between a variety of circulating maternal biomarkers, adverse pregnancy, and perinatal outcomes, screening tests based on these biomarkers, incorporating maternal characteristics, fetal biophysical or circulatory variables have been developed. However, their clinical utility has yet to be proven. Of the current biomarkers, placental growth factor and soluble fms-like tyrosine kinase 1 appear to have the most promise for placental dysfunction and predictive utility for FGR.

show abstract

“…To date, prenatal biochemical screening has largely focused on fetal screening and, to a lesser extent, placenta-related obstetrical outcomes. 32,33 Millions of women worldwide will continue to undergo prenatal biochemical screening; therefore, there exists an opportunity to better estimate a woman's long-term risk of SMM. This study was not designed to test whether prenatal biochemical screening offers additive information over known risk factors for SMM, such as maternal age, high or low body mass index, 23,34 or other risk factors.…”

Section: Clinical and Policy Relevancementioning

confidence: 99%

Risk of Severe Maternal Morbidity or Death in Relation to Prenatal Biochemical Screening: Population-Based Cohort Study

et al. 2019

View full text Add to dashboard Cite

Objective To examine whether prenatal biochemical screening analytes are associated with an increased risk of severe maternal morbidity (SMM) or maternal mortality. Study Design This population-based cohort study includes all women in Ontario, Canada, who underwent prenatal screening from 2001 to 2011. Increasing fifth percentiles of the multiple of the median (MoM) for alphafetoprotein (AFP), total human chorionic gonadotropin, unconjugated estriol (uE3), dimeric inhibin-A (DIA), and pregnancy-associated plasma protein A were evaluated. An abnormally high concentration (>95th percentile MoM) for each analyte, individually and combined, was also evaluated. The main outcome assessed was the adjusted relative risk (aRR) of SMM or maternal mortality from 20 weeks' gestation up to 26 weeks thereafter. Results Among 748,972 pregnancies, 11,177 resulted in SMM or maternal mortality (1.5%). Except for uE3, the aRR of SMM or maternal mortality increased in association with increasing fifth percentiles of the MoM for all analytes. AFP (aRR: 2.10; 95% confidence interval [CI]: 1.97–2.25) and DIA (aRR: 2.33; 95% CI: 1.98–2.74) > 95th versus ≤ 5th percentile of the MoM were especially associated with SMM or death. Conclusion Women with abnormally high concentrations of certain prenatal biochemical analytes may be at a higher risk of SMM or death in pregnancy or postpartum.

show abstract

Maternal serum placental growth factor combined with second trimester aneuploidy screening to predict small-for-gestation neonates without preeclampsia

Abstract: SGA neonates in the absence of PE could potentially be identified at 15-18 weeks of pregnancy.

Cited by 4 publications

References 22 publications

Are serum levels of inhibin A in second trimester predictors of adverse pregnancy outcome?

Are serum levels of inhibin A in second trimester predictors of adverse pregnancy outcome?

Circulating biomarkers associated with placental dysfunction and their utility for predicting fetal growth restriction

Risk of Severe Maternal Morbidity or Death in Relation to Prenatal Biochemical Screening: Population-Based Cohort Study

Contact Info

Product

Resources

About